BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

438 related articles for article (PubMed ID: 33983835)

  • 21. Transthyretin cardiac amyloidosis: an update on diagnosis and treatment.
    Yamamoto H; Yokochi T
    ESC Heart Fail; 2019 Dec; 6(6):1128-1139. PubMed ID: 31553132
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cardiac amyloidosis: An underdiagnosed/underappreciated disease.
    Manolis AS; Manolis AA; Manolis TA; Melita H
    Eur J Intern Med; 2019 Sep; 67():1-13. PubMed ID: 31375251
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Understanding and recognizing cardiac amyloidosis.
    McVeigh T; Tennyson C
    JAAPA; 2020 Oct; 33(10):16-20. PubMed ID: 32941304
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Transthyretin amyloidosis: an under-recognized neuropathy and cardiomyopathy.
    Galant NJ; Westermark P; Higaki JN; Chakrabartty A
    Clin Sci (Lond); 2017 Mar; 131(5):395-409. PubMed ID: 28213611
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A review of transthyretin cardiac amyloidosis.
    Jhawar N; Moreno JCL; Chirila R
    Rom J Intern Med; 2023 Mar; 61(1):28-34. PubMed ID: 36278951
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cardiac Care of Patients with Cardiac Amyloidosis.
    Itzhaki Ben Zadok O; Kornowski R
    Acta Haematol; 2020; 143(4):343-351. PubMed ID: 32408301
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epidemiology and clinical manifestations of cardiac amyloidosis.
    Bajwa F; O'Connor R; Ananthasubramaniam K
    Heart Fail Rev; 2022 Sep; 27(5):1471-1484. PubMed ID: 34694575
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Ultrastructure of Tissue Damage by Amyloid Fibrils.
    Koike H; Katsuno M
    Molecules; 2021 Jul; 26(15):. PubMed ID: 34361762
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tafamidis: a selective transthyretin stabilizer to treat wild-type ATTR amyloidosis and hereditary ATTR amyloidosis with cardiomyopathy.
    Paton DM
    Drugs Today (Barc); 2019 Dec; 55(12):727-734. PubMed ID: 31942875
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Advances in Diagnosis and Treatment of Cardiac and Renal Amyloidosis.
    Law S; Fontana M; Gillmore JD
    Cardiol Clin; 2021 Aug; 39(3):389-402. PubMed ID: 34247752
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Screening for Transthyretin Amyloid Cardiomyopathy in Everyday Practice.
    Witteles RM; Bokhari S; Damy T; Elliott PM; Falk RH; Fine NM; Gospodinova M; Obici L; Rapezzi C; Garcia-Pavia P
    JACC Heart Fail; 2019 Aug; 7(8):709-716. PubMed ID: 31302046
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cardiac amyloidosis: a practical approach to diagnosis and management.
    Kapoor P; Thenappan T; Singh E; Kumar S; Greipp PR
    Am J Med; 2011 Nov; 124(11):1006-15. PubMed ID: 22017778
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments.
    Sekijima Y
    J Neurol Neurosurg Psychiatry; 2015 Sep; 86(9):1036-43. PubMed ID: 25604431
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Transthyretin Cardiac Amyloidosis: An Evolution in Diagnosis and Management of an "Old" Disease.
    Smiley DA; Rodriguez CM; Maurer MS
    Cardiol Clin; 2022 Nov; 40(4):541-558. PubMed ID: 36210137
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The diagnostic challenges of cardiac amyloidosis: A practical approach to the two main types.
    Varga C; Dorbala S; Lousada I; Polydefkis MJ; Wechalekar A; Maurer MS; Comenzo RL
    Blood Rev; 2021 Jan; 45():100720. PubMed ID: 32616304
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Diagnosis and treatment of cardiac transthyretin amyloidosis. Innovative therapy with tafamidis.].
    Legrand D; Nyssen A; Jackers L; Brogneaux C; Pirotte I; Grayet D; Lacremans D; Magnée M
    Rev Med Liege; 2022 Jan; 77(1):63-68. PubMed ID: 35029343
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Canadian Cardiovascular Society/Canadian Heart Failure Society Joint Position Statement on the Evaluation and Management of Patients With Cardiac Amyloidosis.
    Fine NM; Davis MK; Anderson K; Delgado DH; Giraldeau G; Kitchlu A; Massie R; Narayan J; Swiggum E; Venner CP; Ducharme A; Galant NJ; Hahn C; Howlett JG; Mielniczuk L; Parent MC; Reece D; Royal V; Toma M; Virani SA; Zieroth S
    Can J Cardiol; 2020 Mar; 36(3):322-334. PubMed ID: 32145862
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Histological Typing in Patients With Cardiac Amyloidosis: JACC Review Topic of the Week.
    Gonzalez-Lopez E; McPhail ED; Salas-Anton C; Dominguez F; Gertz MA; Dispenzieri A; Dasari S; Milani P; Verga L; Grogan M; Palladini G; Garcia-Pavia P
    J Am Coll Cardiol; 2024 Mar; 83(11):1085-1099. PubMed ID: 38479957
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac Amyloidosis.
    Maurer MS; Bokhari S; Damy T; Dorbala S; Drachman BM; Fontana M; Grogan M; Kristen AV; Lousada I; Nativi-Nicolau J; Cristina Quarta C; Rapezzi C; Ruberg FL; Witteles R; Merlini G
    Circ Heart Fail; 2019 Sep; 12(9):e006075. PubMed ID: 31480867
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement From the American Heart Association.
    Kittleson MM; Maurer MS; Ambardekar AV; Bullock-Palmer RP; Chang PP; Eisen HJ; Nair AP; Nativi-Nicolau J; Ruberg FL;
    Circulation; 2020 Jul; 142(1):e7-e22. PubMed ID: 32476490
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.